Daewoong Pharmaceutical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Daewoong Pharmaceutical şirketinin toplam hissedar öz sermayesi ₩934.8B ve toplam borcu ₩548.8B olup, bu da borç-öz sermaye oranını 58.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₩1,877.4B ve ₩942.5B dir. Daewoong Pharmaceutical 'in FAVÖK'ü ₩128.6B faiz karşılama oranı 32.1 dur. Şirketin ₩110.3B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

58.7%

Borç/özkaynak oranı

₩548.75b

Borç

Faiz karşılama oranı	32.1x
Nakit	₩110.31b
Eşitlik	₩934.81b
Toplam yükümlülükler	₩942.54b
Toplam varlıklar	₩1.88t

Son finansal sağlık güncellemeleri

Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly

Oct 15

We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt

Jul 04

Recent updates

Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly

Oct 15

Daewoong Pharmaceutical Co., Ltd (KRX:069620) Shares Could Be 49% Below Their Intrinsic Value Estimate

Aug 13

Daewoong Pharmaceutical Co., Ltd's (KRX:069620) 27% Price Boost Is Out Of Tune With Earnings

Jul 24

We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt

Jul 04

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: A069620 'nin kısa vadeli varlıkları ( ₩589.6B ) kısa vadeli yükümlülüklerini ( ₩588.5B ) aşıyor.

Uzun Vadeli Yükümlülükler: A069620 şirketinin kısa vadeli varlıkları ( ₩589.6B ) uzun vadeli yükümlülüklerini ( ₩354.1B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: A069620 'nin net borç/öz sermaye oranı ( 46.9% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: A069620 'nin borç/öz sermaye oranı son 5 yılda 62.4% seviyesinden 58.7% seviyesine düştü.

Borç Kapsamı: A069620 'nin borcu işletme nakit akışı ( 15.4% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: A069620 'in borcuna ilişkin faiz ödemeleri EBIT ( 32.1 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Daewoong Pharmaceutical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly

We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt

Recent updates

Price target increased by 7.8% to ₩190,000

Price target increased by 11% to ₩176,250

Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly

Investor sentiment improves as stock rises 15%

Investor sentiment improves as stock rises 19%

Daewoong Pharmaceutical Co., Ltd (KRX:069620) Shares Could Be 49% Below Their Intrinsic Value Estimate

Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-In-Class PRS Inhibitor, Bersiporocin

Daewoong Pharmaceutical Co., Ltd's (KRX:069620) 27% Price Boost Is Out Of Tune With Earnings

Investor sentiment improves as stock rises 19%

We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt

Consensus EPS estimates increase by 25%

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Upcoming dividend of ₩600 per share at 0.5% yield

Daewoong Pharmaceutical Announces Successful 'Extra Strength' Results of US Phase 2 Clinical Trial for High-Dose Administration of Nabota

Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative GLP-1 Obesity Treatment with Advanced Microneedle Technology for Sustained Weekly Efficacy

Daewoong Therapeutics Gets Mfds Nod for Phase 1 Ind for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema

Price target decreased by 7.5% to ₩171,083

Daewoong Pharmaceutical Obtains Approval for SGLT2i + Metformin Combination Drug Envlomet

New minor risk - Shareholder dilution

Avacta Group Plc (AIM:AVCT) acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd (KOSE:A069620).

Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023

Full year 2022 earnings released: EPS: ₩3,816 (vs ₩2,227 in FY 2021)

Now 20% undervalued after recent price drop

Price target decreased by 7.4% to ₩205,714

Investor sentiment deteriorates as stock falls 18%

Daewoong Pharmaceutical Begins the First Administration of Bersiporocin

Daewoong Pharmaceutical Co.,Ltd Submits NDA for Its Global New Drug Fexuclue in 11 Countries, Only 1 Year After Approval in Korea

Consensus forecasts updated

Upcoming dividend of ₩600 per share

Daewoong Pharmaceutical Announces Success in Developing New Antidiabetic Medication

Now 20% undervalued after recent price drop

Less than half of directors are independent

Daewoong Pharmaceutical Announces Phase 3 Clinical Trial Results of New Diabetes Treatment Enavogliflozin

Investor sentiment improved over the past week

Price target increased to ₩235,714

Daewoong Pharmaceutical Announces US FDA Clearance of IND Application for DWP213388, First-In-Class Irreversible Oral Dual Acting Inhibitor for Autoimmune Diseases

Price target increased to ₩235,000

Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug

Investor sentiment improved over the past week

Less than half of directors are independent

Daewoong Pharmaceutical Submits NDA for its Global New Drug Fexuclue Tablets to the Philippines

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Daewoong pharmaceutical Co.,Ltd Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy

Daewoong Pharmaceutical Released Positive Phase 3 Topline Results for New Antidiabetic Drug

Upcoming dividend of ₩600 per share

Price target increased to ₩199,000

Daewoong Pharmaceutical Publishes Results of First Clinical Study of SGLT-2 Inhibitor 'Enavogliflozin' for Canine Diabetes

Daewoong Pharmaceutical of South Korea Announces PRS-Inhibitor for Idiopathic Pulmonary Fibrosis Shows Promising Result in Early Stage Clinical Test

First quarter 2021 earnings released: ₩2,139 loss per share (vs ₩65.00 profit in 1Q 2020)

Price target increased to ₩147,143

Evolus, Inc. and Daewoong Pharmaceuticals Co., Ltd. Enter into Settlement Agreement

Full year 2020 earnings released: EPS ₩1,196 (vs ₩2,132 in FY 2019)

Daewoong pharmaceutical Co.,Ltd., Annual General Meeting, Mar 26, 2021

New 90-day low: ₩121,000

Price target raised to ₩126,625

New 90-day high: ₩119,000

Third quarter 2020 earnings released: EPS ₩223

Price target lowered to ₩110,000

New 90-day low: ₩91,900

Daewoong Pharmaceutical Announces Korea's First-Ever SGLT2 Inhibitor for Diabetes Treatment

Price target lowered to ₩123,214

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin